Letter to the EditorAdjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms
Section snippets
Case 1
AA was a 36 year-old Korean-American male with a 17-year history of Catatonic Schizophrenia (DSM-IV SCID diagnosis). After two years of clozapine and only partial improvement, several four to six week trials of adjunct medication were tried including topiramate (100 mg BID), risperidone (4 mg daily), olanzapine (15 mg daily), lithium (blood level of 0.74 mEq/L), and lamotrigine (200 mg daily). Aripiprazole was added with some benefit (15 mg/day). Minocycline was added and titrated to 100 mg BID, six
Case 2
BB was a 26 year-old Caucasian male with a diagnosis of schizophrenia (DSM-IV SCID diagnosis) with catatonic features since age 18. He was treated with 350 mg clozapine for three years with a recent clozapine plasma level of 424 ng/ml. His symptoms remained severe, with near continuous auditory and visual hallucinations, severely distressing feelings of external control and thought broadcasting, pre-occupying somatic and persecutory delusions, and moderately severe emotional withdrawal, affective
Discussion
Both cases suggest that adjunctive minocycline to clozapine is safe and effective in patients with schizophrenia who continue to have symptoms despite adequate clozapine treatment. Both patients had improvements in their symptoms, notably robust improvements in negative symptoms, and reported “just feeling better” on their medications. This is one of the first reports of adjunct minocycline to clozapine treatment in patients with persistent symptoms. Levkovitz et al. (Levkovitz et al., 2010)
Role of funding source
There was no funding for this case report.
Contributors
Dr. Kelly wrote the manuscript first draft and originated the idea of minocycline treatment. Drs. Richardson and Vyas treated the patients, performed the ratings and assisted in manuscript preparation. Drs. Buchanan, Wehring and Koola were part of the clinical team monitoring and assisted with the manuscript preparation. All authors have contributed to and approved the final manuscript.
Conflict of interest
Author Robert Buchanan has consulted for Abbott, Cypress Bioscience, Glaxo-Smith-Kline, Sanofi-Aventis, Schering-Plough, and Takeda. Dr. Buchanan is a member of Advisory Boards for Abbott, Astellas, Astra-Zeneca Merck, Pfizer, Roche, Solvay Pharmaceuticals, Inc., Takeda, and Wyeth. Dr. Buchanan is a DSMB member for Pfizer, Cephalon, and Otsuka.
All other authors have nothing to declare no conflicts of interest.
Acknowledgments
The authors have no acknowledgments.
References (13)
- et al.
Functional neuroimaging of minocycline's effect in a patient with schizophrenia
Prog. Neuropsychopharmacol. Biol. Psychiatry
(2010) - et al.
Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline
Prog. Neuropsychopharmacol. Biol. Psychiatry
(2008) - et al.
Minocycline, schizophrenia and GluR1 glutamate receptors
Prog. Neuropsychopharmacol. Biol. Psychiatry
(2009) - et al.
Possible antipsychotic effects of minocycline in patients with schizophrenia
Prog. Neuropsychopharmacol. Biol. Psychiatry
(2007) - et al.
The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis
Schizophr. Res.
(2009) - et al.
The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study
Schizophr. Res.
(2007)
Cited by (42)
The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial
2019, Schizophrenia ResearchCitation Excerpt :Our negative results are similar to those of a recently published clinical trials of add-on minocycline in schizophrenia (Deakin et al., 2018). These results contradict those of other authors who reported that minocycline is efficacious for negative symptoms (Chaudhry et al., 2012; Ghanizadeh et al., 2014; Kelly et al., 2011; Khodaie-Ardakani et al., 2014; Levkovitz et al., 2010; Liu et al., 2014; Miyaoka et al., 2008), meta-analyzed in Oya et al.'s paper (Oya et al., 2014). Some of these studies also showed efficacy for PANSS total and PANSS General Psychopathology (Khodaie-Ardakani et al., 2014; Liu et al., 2014), our results did not.
Treatment of negative symptoms: Where do we stand, and where do we go?
2017, Schizophrenia ResearchAdjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials
2017, European NeuropsychopharmacologyInflammation and immunity in schizophrenia: Implications for pathophysiology and treatment
2015, The Lancet PsychiatryEffects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia
2015, Schizophrenia ResearchCitation Excerpt :Subsequently, a case report and an open study with the addition of minocycline to the usual antipsychotic treatment of patients with schizophrenia showed significant improvement in positive, negative and cognitive symptoms (Miyaoka et al., 2007, 2008). Adjunctive minocycline to clozapine was also effective in improving positive and negative symptoms of two super-refractory patients (Kelly et al., 2011). Additionally, a randomized double-blind placebo-controlled clinical trial of minocycline add-on treatment showed an improvement in negative and cognitive symptoms in patients with schizophrenia (Levkovitz et al., 2010), and another randomized double-blind placebo-controlled clinical trial demonstrated an improvement mainly in the negative symptoms (Chaudhry et al., 2012).